The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | EJC Skin Cancer |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824001770 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846159035352481792 |
|---|---|
| author | L. Mortier N. Meyer J.-J. Grob M. Pouriel D. de Carpentier P. Saïag |
| author_facet | L. Mortier N. Meyer J.-J. Grob M. Pouriel D. de Carpentier P. Saïag |
| author_sort | L. Mortier |
| collection | DOAJ |
| format | Article |
| id | doaj-art-7ddb19baf4b54bf8936ac13a0cd255e7 |
| institution | Kabale University |
| issn | 2772-6118 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Skin Cancer |
| spelling | doaj-art-7ddb19baf4b54bf8936ac13a0cd255e72024-11-24T04:15:10ZengElsevierEJC Skin Cancer2772-61182024-01-012100189The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanomaL. Mortier0N. Meyer1J.-J. Grob2M. Pouriel3D. de Carpentier4P. Saïag5CHU Lille, Lille, FranceClinique Médipôle Garonne, Toulouse, FranceAP-HM, Marseille, FranceIT&Mstats provided for Novartis, Boulogne-Billancourt, FranceNovartis, Rueil-Malmaison, FranceAmbroise Paré Hospital, Boulogne-Billancourt, Francehttp://www.sciencedirect.com/science/article/pii/S2772611824001770 |
| spellingShingle | L. Mortier N. Meyer J.-J. Grob M. Pouriel D. de Carpentier P. Saïag The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma EJC Skin Cancer |
| title | The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma |
| title_full | The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma |
| title_fullStr | The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma |
| title_full_unstemmed | The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma |
| title_short | The RoMEO study: a real-world, observational, prospective investigation of dabrafenib and trametinib combination treatment in patients with BRAF V600 unresectable or metastatic cutaneous melanoma |
| title_sort | romeo study a real world observational prospective investigation of dabrafenib and trametinib combination treatment in patients with braf v600 unresectable or metastatic cutaneous melanoma |
| url | http://www.sciencedirect.com/science/article/pii/S2772611824001770 |
| work_keys_str_mv | AT lmortier theromeostudyarealworldobservationalprospectiveinvestigationofdabrafenibandtrametinibcombinationtreatmentinpatientswithbrafv600unresectableormetastaticcutaneousmelanoma AT nmeyer theromeostudyarealworldobservationalprospectiveinvestigationofdabrafenibandtrametinibcombinationtreatmentinpatientswithbrafv600unresectableormetastaticcutaneousmelanoma AT jjgrob theromeostudyarealworldobservationalprospectiveinvestigationofdabrafenibandtrametinibcombinationtreatmentinpatientswithbrafv600unresectableormetastaticcutaneousmelanoma AT mpouriel theromeostudyarealworldobservationalprospectiveinvestigationofdabrafenibandtrametinibcombinationtreatmentinpatientswithbrafv600unresectableormetastaticcutaneousmelanoma AT ddecarpentier theromeostudyarealworldobservationalprospectiveinvestigationofdabrafenibandtrametinibcombinationtreatmentinpatientswithbrafv600unresectableormetastaticcutaneousmelanoma AT psaiag theromeostudyarealworldobservationalprospectiveinvestigationofdabrafenibandtrametinibcombinationtreatmentinpatientswithbrafv600unresectableormetastaticcutaneousmelanoma AT lmortier romeostudyarealworldobservationalprospectiveinvestigationofdabrafenibandtrametinibcombinationtreatmentinpatientswithbrafv600unresectableormetastaticcutaneousmelanoma AT nmeyer romeostudyarealworldobservationalprospectiveinvestigationofdabrafenibandtrametinibcombinationtreatmentinpatientswithbrafv600unresectableormetastaticcutaneousmelanoma AT jjgrob romeostudyarealworldobservationalprospectiveinvestigationofdabrafenibandtrametinibcombinationtreatmentinpatientswithbrafv600unresectableormetastaticcutaneousmelanoma AT mpouriel romeostudyarealworldobservationalprospectiveinvestigationofdabrafenibandtrametinibcombinationtreatmentinpatientswithbrafv600unresectableormetastaticcutaneousmelanoma AT ddecarpentier romeostudyarealworldobservationalprospectiveinvestigationofdabrafenibandtrametinibcombinationtreatmentinpatientswithbrafv600unresectableormetastaticcutaneousmelanoma AT psaiag romeostudyarealworldobservationalprospectiveinvestigationofdabrafenibandtrametinibcombinationtreatmentinpatientswithbrafv600unresectableormetastaticcutaneousmelanoma |